| 1 |
34791815 | Best regimens for treating chemo-naïve incurable squamous non-small cell lung cancer with a programmed death-ligand 1 tumor proportion score of 1%-49%: A network meta-analysis. | 2022 Jan |
1 |
| 2 |
34825576 | Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis. | 2022 Mar |
3 |
| 3 |
35042068 | Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma. | 2022 Mar |
1 |
| 4 |
35129371 | Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small-cell lung cancer: a network meta-analysis. | 2022 Apr |
1 |
| 5 |
35170879 | Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis. | 2022 Feb 16 |
1 |
| 6 |
35598358 | The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. | 2022 May 19 |
2 |
| 7 |
32361873 | VEGF inhibition in urothelial cancer: the past, present and future. | 2021 Mar |
1 |
| 8 |
32954856 | Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. | 2021 Feb |
3 |
| 9 |
33382454 | Efficacy and safety of PD1/PDL1 blockade with platinum-based chemotherapy for extensive small cell lung cancer: A pooled analysis of randomized trials. | 2021 May |
1 |
| 10 |
33523301 | Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. | 2021 Aug |
1 |
| 11 |
33545805 | Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report. | 2021 Jan |
1 |
| 12 |
33569311 | In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit. | 2021 Jan |
2 |
| 13 |
33687763 | FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer. | 2021 May |
1 |
| 14 |
33839362 | Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. | 2021 Jul |
1 |
| 15 |
33869015 | Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials. | 2021 |
1 |
| 16 |
33894335 | Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. | 2021 Jul |
1 |
| 17 |
33930176 | Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. | 2021 Apr 30 |
2 |
| 18 |
34262873 | Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study. | 2021 |
2 |
| 19 |
34265431 | Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. | 2021 Nov |
1 |
| 20 |
34620772 | The emerging treatment landscape of advanced urothelial carcinoma. | 2021 Dec 1 |
1 |
| 21 |
34637432 | Immunotherapy for small cell lung cancer: established applications and novel approaches. | 2021 Oct |
1 |
| 22 |
34646363 | Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses. | 2021 |
1 |
| 23 |
34734033 | Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives. | 2021 Sep |
1 |
| 24 |
31853007 | PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma. | 2020 Mar |
1 |
| 25 |
31966052 | PD-L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer. | 2020 Feb |
2 |
| 26 |
32078962 | Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. | 2020 Apr |
2 |
| 27 |
32150489 | Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. | 2020 May 10 |
2 |
| 28 |
32527769 | Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer. | 2020 Jul |
2 |
| 29 |
32552295 | Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. | 2020 Dec |
2 |
| 30 |
32635291 | PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis. | 2020 Jul 3 |
1 |
| 31 |
32646443 | Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. | 2020 Jul 9 |
1 |
| 32 |
32670420 | Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy. | 2020 |
1 |
| 33 |
32706170 | Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer. | 2020 Sep |
1 |
| 34 |
32720019 | Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer. | 2020 Jul 27 |
1 |
| 35 |
32801904 | Influence of Programmed Death Ligand-1-Gene Polymorphism rs822336 on the Prognosis and Safety of Postoperative Patients with NSCLC Who Received Platinum-Based Adjuvant Chemotherapy. | 2020 |
2 |
| 36 |
32897000 | Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX-2 and PD-L1. | 2020 Dec 14 |
1 |
| 37 |
32914866 | Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. | 2020 Nov 15 |
2 |
| 38 |
32921017 | [Influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy]. | 2020 Sep 15 |
5 |
| 39 |
32922610 | The association of PD-L1 gene polymorphisms with non-small-cell lung cancer susceptibility and clinical outcomes in a Chinese population. | 2020 |
1 |
| 40 |
32966352 | [Immunotherapy of lung cancer]. | 2020 Sep 23 |
2 |
| 41 |
33037118 | Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. | 2020 Oct |
3 |
| 42 |
33073546 | Genetic variants as predictors of toxicity and response in patients with non-small cell lung cancer undergoing first-line platinum-based chemotherapy: Design of the multicenter PGxLUNG study. | 2020 Dec |
1 |
| 43 |
33316104 | Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. | 2020 Dec 14 |
2 |
| 44 |
30374610 | Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. | 2019 Sep |
1 |
| 45 |
30428640 | Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer. | 2019 Jul |
3 |
| 46 |
30565086 | SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018). | 2019 Jan |
1 |
| 47 |
30664989 | A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial. | 2019 May |
1 |
| 48 |
30851984 | The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. | 2019 Jun |
1 |
| 49 |
30954906 | Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. | 2019 May |
1 |
| 50 |
31130676 | Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports. | 2019 May 26 |
1 |